Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 22;11:14931. doi: 10.1038/s41598-021-94393-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The interactions between PKA and ERK (A,B), PKA and RSK (C,D), RSK and p38 MAPK (E). A1, Protocol for applying the PKA inhibitor KT5720 with 5 min 5-HT. A2, Representative confocal images of pERK in SNs at 45 min post-onset of 5-HT, in the absence or presence of KT5720. A3, Summary data. KT5720 significantly decreased pERK induced by 5-HT (n = 10). B1, Protocol for applying the PKA inhibitor Rp-cAMP with 5-HT. B2, Representative confocal images of pERK at 45 min post-onset, in the absence or presence of Rp-cAMP. B3, Summary data. Rp-cAMP significantly decreased pERK induced by 5-HT (n = 6). C1, Protocol. C2, Representative confocal images of pRSK immediately after 5-HT, in the absence or presence of KT5720. C3, Summary data. KT5720 significantly decreased pRSK induced by 5-HT (n = 7). D1, Protocol. D2, Representative confocal images of pRSK immediately after 5-HT, in the absence or presence of Rp-cAMP. D3, Summary data. Rp-cAMP significantly decreased pRSK induced by 5-HT (n = 9). E1, Protocol for applying the MEK inhibitor U0126 with 5-HT. E2, Representative confocal images of pRSK immediately after 5-HT, in the absence or presence of U0126. E3, Summary data. U0126 did not significantly attenuate the increase of pRSK immediately after 5-HT (n = 6). F1, Protocol for applying the RSK inhibitor BI-D1870 (BID) with 5-HT. F2, Representative confocal images of p-p38 MAPK at 45 min post-onset of 5-HT, in the absence or presence of BID. F3, Summary data. BID attenuated the induction of p-p38 MAPK 45 min post-onset of 5-HT (n = 9). Data are represented as mean ± SEM. All scale bars are 40 μm. *p < 0.05.